Managing a cancer diagnosis during pregnancy requires a coordinated, multidisciplinary approach to balance maternal treatment with fetal safety. According to the American College of Obstetricians and Gynecologists (ACOG), cancer occurs in approximately 1 in 1,000 pregnancies, necessitating care from teams including oncologists, maternal-fetal medicine specialists, and neonatologists to optimize outcomes for both patients.
How is cancer treated during pregnancy?
Treatment plans depend heavily on the gestational age and the type of malignancy. The American Cancer Society notes that surgery can generally be performed safely during any trimester. However, chemotherapy is typically avoided during the first trimester due to the risk of congenital malformations during the period of organogenesis. In the second and third trimesters, certain chemotherapy regimens may be administered with careful monitoring, though clinicians often aim to delay treatment until after delivery if the disease progression allows. Radiation therapy is generally avoided throughout pregnancy because of the risk of fetal radiation exposure, which can lead to growth restriction or developmental issues.
What are the primary risks to the fetus?
The primary risks involve both the direct effects of systemic treatments and the consequences of preterm delivery. According to research published in the New England Journal of Medicine, the greatest challenge for the fetus is often iatrogenic prematurity. When oncologists determine that maternal treatment cannot wait, labor may be induced early. While modern neonatal intensive care units have significantly improved survival rates for preterm infants, these babies remain at higher risk for respiratory distress syndrome, necrotizing enterocolitis, and long-term neurodevelopmental complications compared to infants born at term.
How do specialists coordinate care?
Management requires a “tumor board” approach, where specialists review the specific case to align treatment goals. The National Comprehensive Cancer Network (NCCN) guidelines emphasize that the mother’s health is the priority, as maternal survival remains the prerequisite for fetal well-being. Specialists monitor fetal growth through serial ultrasounds and assess placental function, as some malignancies, such as melanoma or leukemia, have a rare potential to metastasize to the placenta, though this is statistically uncommon.
Key Considerations for Patients
- Individualized Planning: There is no “one-size-fits-all” protocol; treatment is tailored to the specific stage of pregnancy and cancer type.
- Multidisciplinary Teams: Care should be centralized at academic medical centers where obstetricians and oncologists frequently collaborate on complex cases.
- Emotional Support: The psychological burden of a dual diagnosis is significant, and standard care protocols often include integrated mental health support for the patient and family.
Moving forward, advancements in immunotherapy and targeted molecular therapies are being evaluated for their safety profiles in pregnant patients. While data remains limited compared to standard chemotherapy, ongoing clinical registries are helping researchers better understand how these newer agents cross the placental barrier and affect fetal development.
Related reading